Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 3: The role of GM-CSF.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 32753517.
- Also identified by DOI 10.3949/ccjm.87a.ccc057.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been used experimentally in patients with acute respiratory distress syndrome. Recombinant GM-CSF administered by direct inhalation is currently being studied in a cohort of patients with advanced COVID-19.